LBT Innovations Ltd (ASX: LBT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

LBT Innovations Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $27.98 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.75 billion
Earnings per share -0.045
Dividend per share N/A
Year To Date Return 27.27%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • LBT Innovations Ltd (ASX: LBT)
    Latest News

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Guess which small cap ASX stock is rocketing 80% today

    What is getting investors excited on Wednesday? Let's find out.

    Read more »

    A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
    Healthcare Shares

    Guess which ASX AI stock rocketed 170% on an AstraZeneca update

    Investors are loving this company's announcement on Wednesday.

    Read more »

    doctor looks out window resting head in hand
    Healthcare Shares

    LBT Innovations (ASX:LBT) share price plummets 14% despite positive update

    The company's shares are off to a bad start this week...

    Read more »

    Healthcare Shares

    Why the LBT Innovations share price is charging higher today

    The LBT Innovations Limited (ASX: LBT) share price is storming higher today after the company announced the first sale of…

    Read more »

    a woman
    Speculative

    Why the LBT Innovations share price rocketed 243% higher on Tuesday

    The LBT Innovations Limited (ASX:LBT) share price was an impressive performer on Tuesday, rising a staggering 243% at one stage...

    Read more »

    a woman
    ⏸️ Investing

    3 fast-growing biotech shares at the top of my watch list

    CSL Limited (ASX:CSL) is the king of biotech shares, but could one of these three fledgling biotechs one day sit…

    Read more »

    a woman
    ⏸️ Investing

    Here's why LBT Innovations Limited shares rocketed 89% today

    LBT Innovations Limited (ASX:LBT) shares are soaring after gaining FDA approval for its Automated Plate Assessment System. But is it…

    Read more »

    ⏸️ Investing

    What investors can learn from LBT Innovations Limited's slump to a seven-month low

    LBT Innovations Limited's (ASX:LBT) painful crash today on news that its French partner is pursuing another interest holds lessons for…

    Read more »

    a woman
    ⏸️ Investing

    4 stocks that soared more than 16% today

    A fall in the ASX index today couldn't spoil these four stocks' day in the sun

    Read more »

    LBT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About LBT Innovations Ltd

    LBT Innovations Ltd is a designer of technology solutions for the medical industry. Its first product, MicroStreak, in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only U.S. FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation. The company operates in Australia, U.S., Sweden, UK, and Germany.

    LBT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Oct 2024 $0.02 $0.00 0.00% 102,578 $0.02 $0.02 $0.02
    03 Oct 2024 $0.02 $0.00 0.00% 515,153 $0.02 $0.02 $0.02
    02 Oct 2024 $0.02 $0.00 0.00% 2,191,992 $0.02 $0.02 $0.02
    01 Oct 2024 $0.02 $0.00 0.00% 2,767,153 $0.02 $0.02 $0.02
    30 Sep 2024 $0.02 $0.00 0.00% 2,894,798 $0.02 $0.02 $0.01
    27 Sep 2024 $0.01 $0.00 0.00% 18,000 $0.01 $0.01 $0.01
    26 Sep 2024 $0.01 $0.00 0.00% 564,349 $0.01 $0.02 $0.01
    24 Sep 2024 $0.01 $0.00 0.00% 760,821 $0.01 $0.02 $0.01
    23 Sep 2024 $0.02 $0.00 0.00% 2,106,164 $0.01 $0.02 $0.01
    20 Sep 2024 $0.01 $0.00 0.00% 950,000 $0.01 $0.01 $0.01
    19 Sep 2024 $0.01 $0.00 0.00% 107,154 $0.01 $0.01 $0.01
    18 Sep 2024 $0.01 $0.00 0.00% 1,146,840 $0.01 $0.01 $0.01
    17 Sep 2024 $0.01 $0.00 0.00% 927,856 $0.01 $0.01 $0.01
    16 Sep 2024 $0.01 $0.00 0.00% 200,000 $0.01 $0.01 $0.01
    13 Sep 2024 $0.01 $0.00 0.00% 71,166 $0.01 $0.01 $0.01
    12 Sep 2024 $0.01 $0.00 0.00% 2,031,192 $0.01 $0.01 $0.01
    11 Sep 2024 $0.01 $0.00 0.00% 255,000 $0.01 $0.01 $0.01
    10 Sep 2024 $0.01 $0.00 0.00% 1,769,361 $0.01 $0.01 $0.01
    09 Sep 2024 $0.01 $0.00 0.00% 1,349,924 $0.01 $0.01 $0.01
    06 Sep 2024 $0.02 $0.00 0.00% 459,281 $0.01 $0.02 $0.01
    05 Sep 2024 $0.01 $0.00 0.00% 740,301 $0.01 $0.02 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    11 Sep 2024 Brenton Barnes Exercise 2,000,000 $10,000
    Exercise of options.
    11 Sep 2024 Brenton Barnes Buy 2,000,000 $10,000
    Exercise of options.
    16 Aug 2024 Brenton Barnes Buy 25,000,000 $125,000
    Exercise of options.
    16 Aug 2024 Brenton Barnes Exercise 33,000,000 $165,000
    Exercise of options.
    16 Aug 2024 Brenton Barnes Buy 8,000,000 $40,000
    Exercise of options.
    16 Aug 2024 Brenton Barnes Sell 7,439,441 $124,208
    On-market trade.
    27 Jun 2024 Rebecca Wilson Buy 6,798,700 $33,993
    Exercise of options.
    27 Jun 2024 Rebecca Wilson Exercise 6,798,700 $33,993
    Exercise of options.
    19 Dec 2023 Brian O'Dwyer Issued 524,379 $31,500
    Director remuneration. VWAP
    19 Dec 2023 Rebecca Wilson Issued 1,250,000 $15,000
    Director remuneration.
    19 Dec 2023 Brenton Barnes Issued 1,031,250 $24,750
    Director remuneration. VWAP
    15 Nov 2023 Brenton Barnes Issued 50,000,000 $250,000
    Rights issue.
    15 Nov 2023 Brenton Barnes Issued 20,000,000 $100,000
    Rights issue.
    15 Nov 2023 Brenton Barnes Issued 70,000,000 $280,000
    Rights issue.
    15 Nov 2023 Damian Lismore Issued 4,160,000 $16,640
    Rights issue. There is typo error for post holding
    15 Nov 2023 Damian Lismore Issued 4,160,000 $20,800
    Rights issue.
    15 Nov 2023 Damian Lismore Transfer 539,494 $2,157
    Off-market transfer. Assuming off - market transfer of shares
    15 Nov 2023 Damian Lismore Transfer 539,494 $2,157
    Off-market transfer. Assuming off - market transfer of shares
    15 Nov 2023 Rebecca Wilson Issued 13,597,400 $54,389
    Rights issue.
    15 Nov 2023 Rebecca Wilson Issued 13,597,400 $67,987
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Wilson Non-Executive Director Jul 2023
    Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations and has significant experience leading companies in important commercial activation phases working with CEOs as both an advisor and Non-executive Director to develop and execute effective business strategies that supports accelerated and sustained growth.
    Mr Brenton John Barnes Chief Executive OfficerManaging Director Aug 2016
    Mr Barnes has been CEO & Managing Director since 2016, responsible for bringing the APAS machine vision technology through product development into commercialisation. The result is a patent protected platform technology that has been proven to automate culture plate reading more accurately than scientists and with improved quality and traceability of results.
    Mr Brian O'Dwyer Non-Executive Director Oct 2021
    Mr O'Dwyer has more than 25 years of experience in the healthcare and laboratory testing industry. Brian brings industry knowledge and expertise in laboratory testing businesses to the Board. His experience spans across the establishment, management, integration and restructuring of both business and commercial operations through the clinical research spectrum.
    Mr Daniel (Dan) Hill Non-Executive Director Dec 2023
    Mr Hill has a background working in finance, funds management and private equity. He is an experienced investor and business owner, with a track record of building successful businesses across a variety of industry sectors.
    Mr Ian Wisenberg Non-Executive Director Oct 2024
    Mr Wisenberg has held C-suite leadership positions with global life science and pharmaceutical companies, as well as an advisor to the industry on growth strategies and M&A. In recent years he led the acquisition of Bridgewest Groups first biologics manufacturing facility and operation from Pfizer in Adelaide, Australia. After the closing of the transaction, he was appointed Chief Executive Officer of the operating entity, BioCina Pty Ltd. Mr Wisenberg has an global network of pharmaceutical and large biotechnology companies with that includes specific relationships in drug manufacturing.
    Mr Ray Ridge Chief Financial OfficerCompany Secretary Feb 2020
    -
    Ray Ridge Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Unicore Investments Pty Ltd 223,190,000 13.79%
    Viking Bcm Pty Ltd 212,665,188 13.14%
    Mr Brenton Barnes 70,000,000 4.32%
    Fabian Wisplinghoff 65,690,100 4.06%
    Hilmar Wisplinghoff 65,690,100 4.06%
    B Moran Pty Ltd 56,414,858 3.49%
    Jatayco Nominees Pty Ltd <Green Sf A/C> 53,452,562 3.30%
    Spiceme Capital Pty Ltd 42,794,034 2.64%
    Mr Mark Frank Capolupo 32,500,000 2.01%
    Hettich Holding Beteiligungs-Und Verwaltungs-Gmbh\C 30,660,377 1.89%
    Chag Pty Ltd 28,000,000 1.73%
    Hawkeye Smsf Pty Ltd 28,000,000 1.73%
    Mr Robert Andrew Finder 25,947,542 1.60%
    Bearay Pty Ltd <Brian Clayton S/F A/C> 25,014,731 1.55%
    Mr Raymond Robert Ridge <Ridge Family A/C> 20,877,089 1.29%
    Parker And Wilson Investments Pty Ltd <Parker And Wilson S/Fund A/C> 20,396,100 1.26%
    KEW Superannuation Fund Pty Ltd <K W Superannuation Fund A/C> 17,424,000 1.08%
    RJE Aerospace Pty Ltd <Equid Super A/C> 16,117,366 1.00%
    Christopher Jordan Shopov and Christopher James Shopov <Helter Skelter A/C> 14,400,000 0.89%
    Mrs Catherine Mary Costello 13,290,272 0.82%

    Profile

    since

    Note